Klin Monbl Augenheilkd 2009; 226(10): R155-R169
DOI: 10.1055/s-0029-1186028
KliMo-Refresher
Rubrikherausgeber: G. Duncker, Halle
© Georg Thieme Verlag KG Stuttgart · New York

Update: Diagnostik und Therapie von Tropenerkrankungen – Teil 2

M. M. Nentwich1 , U. C. Schaller1 , V. Klauß1
  • 1Augenklinik der Ludwig-Maximilians-Universität München
Further Information

Publication History

Publication Date:
20 October 2009 (online)

Prävention vermeidbarer Blindheit – Vision 2020

Wie bereits im Refresher „Update: Diagnostik und Therapie von Tropenerkrankungen – Teil 1“ erwähnt, leistet die Implementierung der Initiative „Vision 2020: The Right to Sight“ (Global Initiative for the Elimination of avoidable Blindness by the Year 2020) einen bedeutenden Beitrag, die weltweite Blindheit zu reduzieren.

Literatur

  • 1 World Health Organization .State of the world's sight: Vision 2020: The right to sight 1999–2005. WHO Library. 2005: 31
  • 2 Control of vitamin A deficiency and xerophthalmia.  World Health Organ Tech Rep Ser. 1982;  672 1-70
  • 3 Muhit M A, Shah S P, Gilbert C E, Foster A. Causes of severe visual impairment and blindness in Bangladesh: a study of 1935 children.  Br J Ophthalmol. 2007;  91 1000-1004
  • 4 Schaller U. Blindheit bei Kindern im Kontext von „Vision 2020 – The Right to Sight“.  Z prakt Augenheilkd. 2005;  26 394-396
  • 5 Gilbert C. Changing challenges in the control of blindness in children.  Eye. 2007;  21 1338-1343
  • 6 Kollmann M. Blindheitsverhütung bei diabetischer Retinopathie und Glaukom in Afrika.  Z prakt Augenheilkd. 2005;  26 415-417
  • 7 World Health Organization .State of the world's sight: Vision 2020: The Right to Sight 1999 – 2005, Executive Summary. WHO Library. 2005: 18
  • 8 Klauss V, Schaller U C. Tropical ophthalmology–prevention and therapy “Vision 2020 – the right to sight”.  Ophthalmologe. 2004;  101 741-763
  • 9 Roodhooft J M. Leading causes of blindness worldwide.  Bull Soc Belge Ophtalmol. 2002;  283 19-25
  • 10 Lynn W A, Lightman S. The eye in systemic infection.  Lancet. 2004;  364 1439-1450
  • 11 Whitcher J P, Srinivasan M, Upadhyay M P. Corneal blindness: a global perspective.  Bull World Health Organ. 2001;  79 214-221
  • 12 Orem J, Otieno M W, Remick S C. AIDS-associated cancer in developing nations.  Curr Opin Oncol. 2004;  16 468-476
  • 13 Bornfeld N, Schuler A, Boloni R et al. Retinoblastoma.  Ophthalmologe. 2006;  103 59-76
  • 14 Kutok J L, Wang F. Spectrum of Epstein-Barr virus-associated diseases.  Annu Rev Pathol. 2006;  1 375-404
  • 15 Beare N A, Taylor T E, Harding S P et al. Malarial retinopathy: a newly established diagnostic sign in severe malaria.  Am J Trop Med Hyg. 2006;  75 790-797
  • 16 Kochar D K, Shubhakaran, Kumawat B L, Vyas S P. Prognostic significance of eye changes in cerebral malaria.  J Assoc Physicians India. 2000;  48 473-477
  • 17 Yam J C, Kwok A K. Ocular toxicity of hydroxychloroquine.  Hong Kong Med J. 2006;  12 294-304
  • 18 Nagpal K C, Asdourian G K, Goldbaum M H et al. The conjunctival sickling sign, hemoglobin S, and irreversibly sickled erythrocytes.  Arch Ophthalmol. 1977;  95 808-811
  • 19 McLeod D S, Merges C, Fukushima A et al. Histopathologic features of neovascularization in sickle cell retinopathy.  Am J Ophthalmol. 1997;  124 455-472
  • 20 Goldberg M F. Retinal neovascularization in sickle cell retinopathy.  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;  83 OP409-OP431
  • 22 Emerson G G, Lutty G A. Effects of sickle cell disease on the eye: clinical features and treatment.  Hematol Oncol Clin North Am. 2005;  19 957-973 ix
  • 23 Trojan H J. Importierte Augenerkrankungen aus den Tropen.  Z prakt Augenheilkd. 2005;  26 419-428
  • 24 Ng W T, Versace P. Ocular association of HIV infection in the era of highly active antiretroviral therapy and the global perspective.  Clin Experiment Ophthalmol. 2005;  33 317-329
  • 25 UNAIDS .AIDS epdemic update: december 2007. UNAIDS. 2007
  • 26 Bartlett J G. Protease inhibitors for HIV infection.  Ann Intern Med. 1996;  124 1086-1088
  • 27 Goldberg D E, Smithen L M, Angelilli A, Freeman W R. HIV-associated retinopathy in the HAART era.  Retina. 2005;  25 633-649
  • 28 Lewallen S, Courtright P. HIV and AIDS and the eye in developing countries: a review.  Arch Ophthalmol. 1997;  115 1291-1295
  • 29 Sellitti T P, Huang A J, Schiffman J, Davis J L. Association of herpes zoster ophthalmicus with acquired immunodeficiency syndrome and acute retinal necrosis.  Am J Ophthalmol. 1993;  116 297-301
  • 30 Kestelyn P. The epidemiology of CMV retinitis in Africa.  Ocul Immunol Inflamm. 1999;  7 173-177
  • 31 Biswas J, Madhavan H N, George A E et al. Ocular lesions associated with HIV infection in India: a series of 100 consecutive patients evaluated at a referral center.  Am J Ophthalmol. 2000;  129 9-15
  • 32 Balo K P, Amoussou Y P, Bechetoille A et al. Cytomegalovirus retinitis and ocular complications in AIDS patients in Togo.  J Fr Ophtalmol. 1999;  22 1042-1046
  • 33 Martin D F, Dunn J P, Davis J L et al. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel.  Am J Ophthalmol. 1999;  127 329-339
  • 34 Kempen J H, Jabs D A, Wilson L A et al. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome.  Clin Infect Dis. 2003;  37 1365-1373
  • 35 Young S, McCluskey P, Minassian D C et al. Retinal detachment in cytomegalovirus retinitis: intravenous versus intravitreal therapy.  Clin Experiment Ophthalmol. 2003;  31 96-102

Dr. Martin M. Nentwich

Augenklinik der Ludwig-Maximilians-Universität München

Mathildenstraße 8

80336 München

Email: martin.nentwich@med.uni-muenchen.de

    >